WELCOME SPONSORS SPEAKERS PRESENTING COMPANIES 3rd Annual EUROPEAN LIFE SCIENCE CEO FORUM for PARTNERING & INVESTING AWARDS ORGANISATIONS PARTNERING 11-12 February 2010 ConventionPoint, Zurich, Switzerland Conference Guide REGIONAL PARTNERS ORGANISERS EUROPEAN LIFE SCIENCE CEO FORUM www.sachsforum.com WELCOME SPONSORS next Welcome Sachs Associates are delighted to welcome you to the: SPEAKERS PRESENTING COMPANIES 3rd Annual European Life Science CEO Forum for Partnering & Investing 11-12 February 2010 ConventionPoint, Zurich, Switzerland Sachs Associates are delighted to welcome you to the 3rd Annual European Life Science CEO Forum for Partnering & Investing. Following its success from previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas. This exclusive and transactional event complements our Annual Biotech in Europe Investor Forum, held later in the year, but with added focus on Partnering & the pharmaceutical industry, feature presentations from Big Pharma representatives demonstrating their AWARDS ORGANISATIONS PARTNERING current and future partnering strategies through thought-provoking case studies. This year’s programme features a series of panels and presentations from leading investment, pharmaceutical and biotech companies, highlighting the current issues surrounding the evolving M&A market, Vaccines, Medtech Investment and includes special keynote speeches, providing an expert outlook on Europe’s Biotech industry. In addition, the event holds more than 50 company presentations from an exciting and diverse range of publicly listed and private life science companies, looking to raise fi nance and/or fi nd partners. This year’s DyoDelta Life Science Innovation Awards takes place in the evening of the 11th February and the awards recognise exceptional performance in key categories of partnering and fi nancing within the industry.. General Information • The registration desk is open from 8am on both days although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for REGIONAL PARTNERS ORGANISERS each session. • Coffee stations are distributed around the foyer and the presentation rooms throughout the event. • Wireless Internet connection is available throughout the venue for the duration of the event. Please ask for an access code at the registration desk. • The one-to-one meetings are being held in the Bid and Ask room. Please bring with you a copy of your diary. Should you have any queries about your schedule, the laptop situated by the meeting tables is available for your assistance. Request for Presentations Please use the agenda to mark off presentations that you are interested in and email your request to [email protected]. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specifi c presenter. Please note that we DO NOT have copies of the slides that are shown during the conference. WELCOME SPONSORS back Events Diary For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Rosa Lippard on [email protected] SPEAKERS PRESENTING COMPANIES 10th Annual Biotech In Europe Investor Forum 29 - 30 September 2010 • Radisson Blu Hotel • Zurich Airport Back for its 10th year, the Biotech in Europe Investor Forum will once again be held in Zurich, this year at the new venue, the Radisson Blu Hotel by Zurich Airport. Featuring our core sponsors, an audience of over 400 investors, analysts & media, with presenting opportunities for over 60 public and private companies and panel themes including Finance & Investment, Partnering and more, this event is a must for all key players in the Biotech and Pharma industry. The forum will be an excellent platform for companies to raise their profi le by promoting their interests to the larger fi nancial community. Facilitated by its successful one-on-one meeting system and networking receptions, the event will help build strong and meaningful business relationships through face to face communication, and promises to be a great opportunity to meet emerging AWARDS ORGANISATIONS PARTNERING companies, leading global investors, analysts, advisors and Big Pharma representatives. Panel discussions with participation from industry leaders and experts in their sector, makes the Biotech In Europe Investor Forum an excellent way to gain insight and keep up to date with partnering and investment and current industry trends. REGIONAL PARTNERS ORGANISERS WELCOME SPONSORS Host Sponsor SPONSORS next www.six-swiss-exchange.com SPEAKERS PRESENTING COMPANIES Europe’s leading exchange for life sciences companies Swiss fi nancial institutions manage more than one-quarter of the world’s offshore assets and represent the backbone of Switzerland’s strong fi nancial marketplace. As a result, companies listed on SIX Swiss Exchange achieve a high level of visibility within this fi nancially potent investor community. In Switzerland, the life sciences industry in particular has developed over the past years into an internationally recognised and strongly emphasized sectoral focal point: 1. In Europe, SIX Swiss Exchange has grown to become the most important securities exchange in terms of the total market capitalisation of listed life sciences companies: 42% of Europe’s life sciences market capitalisation is attributable to the SIX Swiss Exchange. 2. Collectively, these representatives of the industry account for roughly one-third of the overall market capitalisation of the Swiss equity market. 3. Listed companies in the life sciences fi eld such as Novartis, Roche and Actelion engender an environment that exudes global charisma. 4. Differentiated sector-specifi c indicators such as the SXI LIFE SCIENCES® and SXI Bio+Medtech® indices, as well as the unusually broad analyst coverage of this particular sector, ensure transparency and outstanding visibility. 5. The SIX Swiss Exchange has seen the largest biotech IPOs in Europe in terms of money raised on the AWARDS ORGANISATIONS PARTNERING day of the IPO every year since 2004 and was the only regulated exchange who recently attracted European biotech crossborder-IPOs. With a public offering of securities in Switzerland, and thanks to the tremendous placing power afforded by the Swiss-based investment banks, life science companies gain access to a sectorally experienced, highly competent and broadly international circle of investors. Moreover, the location-specifi c advantages of Switzerland and favourable general conditions contribute to the attractiveness of an initial public offering on the SIX Swiss Exchange: 1. The Continental European marketplace with the most pronounced international orientation 2. A leading fi nancial centre for equity-focused institutional investors 3. A strong private banking industry with a broad investor base 4. Multilingual and multicultural investors 5. Focus on life sciences and small- and mid-caps 6. Numerous banks with established in-house research departments 7. Active bond and derivatives markets 8. An attractive, market-oriented regulatory environment thanks to self-regulation 9. Acceptance of various accounting standards (US-GAAP, IFRS, Swiss GAAP ARR and additional internationally recognised standards) 10. Low foreign exchange risk (listing in various currencies is possible) REGIONAL PARTNERS ORGANISERS Further information on the topic of IPOs on the SIX Swiss Exchange can be accessed at: www.six-swiss-exchange.com/download/about/div_pub/swx_ipoguide_en.pdf Should you have further questions with regard to a public offering of securities, the various stock market segments or any other exchange-related topic, please feel free to contact our Issuer & Investor Relations team. SIX Swiss Exchange Issuer & Investor Relations Selnaustrasse 30, Postfach, CH-8021 Zürich T +41(0)58 854 22 45 F +41(0)58 854 22 40 WELCOME SPONSORS SPONSORS Sponsors back :: next DyoDelta Biosciences www.dyodelta.com SPEAKERS PRESENTING COMPANIES DyoDelta Biosciences Ltd., is a London based company specialising in providing Business Development and Due Diligence support to companies and investors in the Pharma / Biotech sector. DyoDelta Biosciences’ team averages more than 20 years experience per person and more than 150 years of cumulative experience. DyoDelta Biosciences has thousands of contacts at the senior corporate level worldwide and across the life sciences industry. The team’s executives have put together multiple types of deals, including R&D collaborations, strategic alliances, product licensing, acquisitions, disposals, fi nancings and local geography partnering, with NPVs adding to billions of dollars. DyoDelta Biosciences covers Europe, the US and Japan, in guiding and supporting pharma and biotech companies, investors, institutions and organisations in corporate transactions, evaluation and due diligence. Corporate deals with pharma companies are key to progressing development, providing funding, validation and also the trigger to investors for either an IPO or further funding. DyoDelta Biosciences provides support to professional investors (funds) in the pharma and biotech sector the following areas: • Market Research and Analysis • Identifi cation of suitable opportunities • Deal Sourcing • Industry Contacts AWARDS ORGANISATIONS PARTNERING • Commercial & Technical Evaluation • Due Diligence For more information,